Clinical trials
Advanced Pancreatic Adenocarcinoma clinical trials
Below are recruiting advanced pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06705335Recruiting
Pancreatic cancer study: looking at convertase enzymes
This study collects tissue samples from people with pancreatic cancer to study convertase enzymes. It may help us understand how these enzymes affect the disease.
BordeauxAges 18 years+ - NCT06898385RecruitingPhase 1
IX001 TCR-T Cells for Advanced Pancreatic Cancer with KRAS G12V
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06598007RecruitingPhase 1/Phase 2
Studying CT3001 for advanced solid tumors
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Houston, TexasAges 18 years+ - NCT02869802Recruiting
Study types of pancreatic cancer using tumor gene testing
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
Calgary, AlbertaAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06412510RecruitingPhase 1/Phase 2
Exercise before chemo for several cancers
This trial tests a prehab program for older adults with certain cancers before they begin chemotherapy. The program may help you feel stronger and handle treatment better.
Cleveland, OhioAges 65 years+ - NCT07444541RecruitingPhase 1/Phase 2
Study of ANO31905 plus chemo for CLDN18.2-positive pancreatic cancer
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT06895031RecruitingPhase 2
JYP0015 for advanced solid tumors with RAS mutations
This trial tests a new drug called JYP0015 for people with advanced solid tumors that have a specific change in the RAS gene. It aims to see if the drug can help when other treatments have stopped working or caused too many side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03257033RecruitingPhase 3
Gemcitabine through an artery versus by vein after radiation
This study tests whether giving gemcitabine directly into the artery feeding the pancreas (instead of through an IV) works better after you finish radiation therapy. It may help patients by improving how the medicine reaches the tumor while comparing side effects and outcomes between the two delivery methods.
Loma Linda, CaliforniaAges 18 years+ - NCT05776342Recruiting
Markers study for treatment response in pancreatic cancer
This study looks at tumor “markers” (tests on cancer tissue or related information) to understand how you may respond to first-line treatment for pancreatic cancer. Your results may help doctors better predict which treatments work best for different people.
BesançonAges 18 years+ - NCT07235930RecruitingPhase 3
New drug combo for advanced pancreatic cancer
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
Hangzhou, ZhejiangAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Orange, CaliforniaAges 18 years+
Hear when a new Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 237 recruiting advanced pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.